At a glance
ClinicalIndex Comparison Record- ✓Advanced cancer expressing one or more of: GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR
- ✓Life expectancy greater than 12 weeks
- ✓Adequate heart, lung, liver, and kidney function
- ✓Informed consent signed by patient or guardian
- ✕Prior gene therapy
- ✕Severe viral infection including HBV, HCV, HIV
- ✕Known HIV positivity
- ✕Active infectious disease (bacterial, viral, fungal)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial
In Brief
A Phase 1 clinical trial evaluating CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for Lung Cancer and 3 related conditions. Currently recruiting, targeting 30 participants across 2 sites.
Detailed Summary
The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR -CAR-T cell immunotherapy on human cancers will firstly be tested.
Study Details
Timeline
Interventions
CAR-T cells injection: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.